CKD 371
Alternative Names: CKD-371Latest Information Update: 18 Apr 2023
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 18 Apr 2023 Phase-III clinical trials in Type 2 diabetes mellitus (PO), prior to April 2023 (Chong Kun Dang Pharmaceutical pipeline, April 2023)
- 17 Nov 2022 Chong Kun Dang Pharmaceutical completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT05544214)
- 21 Oct 2022 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT05544214)